Table 4: Adverse events of denosumab in GIOP.
Study |
Adverse events/reactions |
|
Denosumab |
Bisphosphonates |
|
Suzuki 2018 |
No serious adverse event, such as hypocalcemia or atypical bone fracture, occurred during the study. |
N/A |
Iseri [32] |
Skin rash (n = 1) |
none |
Akashi [27] |
Not reported |
N/A |
Dore [26] |
Adverse events were comparable between denosumab and placebo groups |
N/A |
Ishiguro [24] |
Hypocalcemia (n = 0) Jaw osteonecrosis (n = 0) |
N/A |
Sawamura [25] |
Upper respiratory infections (n = 2) |
N/A |
Iwamoto [29] |
Herpes zoster (n = 2) |
N/A |
Saag [31] |
Pneumonia (n = 5) Cardiac failure (n = 3) Transient ischemic attack (n = 3) Osteoporosis related fractures (n = 26/398) Malignancy (n = 5) Pyelonephritis acute (n = 1) Anti-denosumab antibody (n = 1) |
Pneumonia (n = 6) Osteoporosis related fractures (n = 23/397) Malignancy (n = 3) Arthralgia (n = 21) Hypertension (n = 13) Diverticulitis (n = 1) Pyelonephritis acute (n = 1) Bronchitis (n = 2) |
Kadoba [33] |
Osteonecrosis of the jaw (n = 1) Transient hypocalcemia (n = 3) |
Osteoporotic fractures (n = 7) Avascular necrosis of femoral head (n = 8) Osteonecrosis of the jaw (n = 1) Transient hypocalcemia (n = 6) |
Tanaka [34] |
Vertebral fracture (n = 2) |
Vertebral fracture (n = 24) |
Yoshi [30] |
Not reported |
Not reported |
Mok [35] |
Fever after injection (n = 1) |
Infective episodes (n = 1) |
N/A- not applicable.